Rationale and design of two phase iiib studies of ocrelizumab at higher than the approved dose in patients with RMS and PPMS

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2020
This article has no abstract
Epistemonikos ID: 72a88445c4ff3e10f5bbcb520faa4ddc0284ea03
First added on: Apr 30, 2026